Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Kosa KM, Cates SC, Hall AJ, Brophy JE, Frasier A. Knowledge of norovirus prevention and control among infection preventionists. Poster presented at the 2014 APIC’s 41st Annual Conference; June 2014. Anaheim, CA. [abstract] Am J Infect Control. 2014 Jun; 42(6):676-8. doi: 10.1016/j.ajic.2014.02.004
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, Papadopoulos G. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011 May 1;39(4):e15-20.
Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infect Control. 2010 Feb;38(1):44-9. doi: 10.1016/j.ajic.2009.04.287.